Kintor Pharma focuses on developing innovative small molecules and biologic drugs for androgen-related diseases with significant unmet needs, including treatments for COVID-19, prostate cancer, alopecia, acne, liver cancer, breast cancer and other conditions. Kintor Pharma's product pipeline includes innovative small molecule drugs, biologics, and combination therapies.The product pipeline consists of seven products undergoing clinical research, including androgen receptor antagonists, ALK-1 monoclonal antibody,AR-PROTAC,PD-L1/TGF-β dual-targeting antiobdy,mTOR inhibitor and Hedgehog/SMO inhibitor. The company also has ongoing preclinical programs in ALK-1/VEGF dual-targeting antibody and c - Myc inhibitors. We are actively seeking partnerships for China and worldwide, welcome to contact us!

　　Tel：+86 512 6263 9916，+86 512 6263 9920

　　Email：BD@kintor.com.cn